A Covid Jab Every Month … Next, Every Day! By Brian Simpson
It has now come down to this. A New Israeli study of two million people shows that the fourth dose vaccine wears off against Omicron after 3-4 weeks and is gone by eight weeks. Hence, one needs a new “booster” around every 30 days to be “safe.” With a multiplicative effect with the threat of adverse effects with each jab, why would one bother?
“ICYMI: You need to be boosted every 30 days to stay "protected"
It seems like telling my blue pill friends NOT to get the vaccine hasn't been working. Should I try a new approach: coaching them to get boosted every 30 days?
New Israeli study of 2 million people shows that the fourth dose vaccine wears off against Omicron after 3-4 weeks and protection is pretty much gone by 8 weeks.
So you’ll need a new “booster” around every 30 days to be “safe.”
Here are a few comments on the video on YouTube:
- My friend is a geriatric nurse and she has patients who have had their fourth dose and they still get COVID and moreover, their crp is high, their wbc is low and their dimers are through the roof (ie 4000).
- “These vaccines are not well- matched for omicron” that’s an understatement, but very well-matched for the company’s profits.
- It’s unbelievable people are making excuses for a product that gives 6 weeks of efficacy and also happens to have the worst side-effect profile of any vaccine and almost of any drug ever.
If getting vaccinated every 30 days doesn’t cause people to wake up, I don’t know what will.
In the comments below, Mathew Crawford points out the following:
That's okay because each injection you get lowers your risk of dying from non-COVID causes, including car accidents and murder, apparently.
He referenced his substack article which refers to a CDC paper which makes this claim (indirectly). Note that I wrote about that exact same CDC paper back on Nov 12, 2021 entitled “FDA discovers Fountain of Youth.”
The public just eats this stuff up apparently. They will continue to do whatever the CDC says, no matter how goofy the advice.”
On January 2, 2022, Israel began administering a fourth dose of BNT162b2 vaccine to persons 60 years of age or older. Data are needed regarding the effect of the fourth dose on rates of confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and of severe coronavirus disease 2019 (Covid-19).
Using the Israeli Ministry of Health database, we extracted data on 1,252,331 persons who were 60 years of age or older and eligible for the fourth dose during a period in which the B.1.1.529 (omicron) variant of SARS-CoV-2 was predominant (January 10 through March 2, 2022). We estimated the rate of confirmed infection and severe Covid-19 as a function of time starting at 8 days after receipt of a fourth dose (four-dose groups) as compared with that among persons who had received only three doses (three-dose group) and among persons who had received a fourth dose 3 to 7 days earlier (internal control group). For the estimation of rates, we used quasi-Poisson regression with adjustment for age, sex, demographic group, and calendar day.
The number of cases of severe Covid-19 per 100,000 person-days (unadjusted rate) was 1.5 in the aggregated four-dose groups, 3.9 in the three-dose group, and 4.2 in the internal control group. In the quasi-Poisson analysis, the adjusted rate of severe Covid-19 in the fourth week after receipt of the fourth dose was lower than that in the three-dose group by a factor of 3.5 (95% confidence interval [CI], 2.7 to 4.6) and was lower than that in the internal control group by a factor of 2.3 (95% CI, 1.7 to 3.3). Protection against severe illness did not wane during the 6 weeks after receipt of the fourth dose. The number of cases of confirmed infection per 100,000 person-days (unadjusted rate) was 177 in the aggregated four-dose groups, 361 in the three-dose group, and 388 in the internal control group. In the quasi-Poisson analysis, the adjusted rate of confirmed infection in the fourth week after receipt of the fourth dose was lower than that in the three-dose group by a factor of 2.0 (95% CI, 1.9 to 2.1) and was lower than that in the internal control group by a factor of 1.8 (95% CI, 1.7 to 1.9). However, this protection waned in later weeks.
Rates of confirmed SARS-CoV-2 infection and severe Covid-19 were lower after a fourth dose of BNT162b2 vaccine than after only three doses. Protection against confirmed infection appeared short-lived, whereas protection against severe illness did not wane during the study period.”